Similar articles

• Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.

  Lim SH, Lee JY, Sun JM, Ahn JS, Park K, Ahn MJ. Lim SH, et al. J Thorac Oncol. 2014 Apr;9(4):506-11. doi: 10.1097/JTO.0000000000000095. J Thorac Oncol. 2014. PMID: 24736073
• A phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705.

  Yoshioka H, Hotta K, Kiura K, Takigawa N, Hayashi H, Harita S, Kuyama S, Segawa Y, Kamei H, Umemura S, Bessho A, Tabata M, Tanimoto M; Okayama Lung Cancer Study Group. Yoshioka H, et al. J Thorac Oncol. 2010 Jan;5(1):99-104. doi: 10.1097/JTO.0b013e3181c20063. J Thorac Oncol. 2010. PMID: 19898258 Clinical Trial.
• First case of A859T epidermal growth factor receptor mutation responding to erlotinib.

  Le Maignan L, Mirebeau-Prunier D, Vervueren L, Jeanfaivre T, Urban T, Hureaux J. Le Maignan L, et al. J Thorac Oncol. 2011 Mar;6(3):639-40. doi: 10.1097/JTO.0b013e3182037c0c. J Thorac Oncol. 2011. PMID: 21317745 No abstract available.
• Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.

  Amler LC, Goddard AD, Hillan KJ. Amler LC, et al. Cold Spring Harb Symp Quant Biol. 2005;70:483-8. doi: 10.1101/sqb.2005.70.048. Cold Spring Harb Symp Quant Biol. 2005. PMID: 16869787 Review.
• Lung adenocarcinoma: lessons in translation from bench to bedside.

  Sangodkar J, Katz S, Melville H, Narla G. Sangodkar J, et al. Mt Sinai J Med. 2010 Nov-Dec;77(6):597-605. doi: 10.1002/msj.20226. Mt Sinai J Med. 2010. PMID: 21105123 Review.